Publicacións en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (2)

2020

  1. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

    Lung Cancer, Vol. 150, pp. 62-69

2012

  1. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

    Anti-Cancer Drugs, Vol. 23, Núm. 2, pp. 239-246